Ultralow Dose Rituximab Combined With <scp>IVIG</scp> Is Safe and Effective in Pemphigus Vulgaris: Single‐Center Review of 24 Patients
We present a combined ultralow dose rituximab and intravenous immunoglobulin protocol for the treatment of moderate to severe pemphigus vulgaris which has been proven to be safe and effective in a series of 24 rituximab naïve patients.
Authors
- Andrew Awad (ORCID: https://orcid.org/0000-0003-4604-1062)
- Laura Scardamaglia (ORCID: https://orcid.org/0000-0001-6160-8886)
- J. Kenneth McClatchy (ORCID: https://orcid.org/0009-0008-7139-3493)
- Tami Yap (ORCID: https://orcid.org/0000-0001-8412-1114)
Institutions
- The Royal Melbourne Hospital (AU)
- Royal Children's Hospital (AU)
- The University of Melbourne (AU)
- Flinders University (AU)
- Western Health (AU)
Publication Details
- Journal
- Australasian Journal of Dermatology
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1111/ajd.70003
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00